SCHEDULE: Laurence Lytton Boosts Aprea Therapeutics Stake to 9.9%

Laurence W. Lytton has increased his beneficial ownership in Aprea Therapeutics, Inc. to 9.9% of the common stock, following a purchase in an at-the-money offering.

Summary

• Laurence W. Lytton reported beneficial ownership of 681,837 shares of Aprea Therapeutics, Inc. common stock.
• This represents 9.9% of the company's outstanding common stock.
• The ownership percentage is calculated based on 6,870,673 shares outstanding as of November 13, 2025.
• The total shares outstanding include 6,310,673 shares reported on November 11, 2025, and an additional 560,000 shares purchased by Mr. Lytton.
• Mr. Lytton acquired 560,000 shares from Aprea Therapeutics in an at-the-money offering on November 13, 2025.
• He holds sole voting and dispositive power over 677,618 shares and shared power over 4,219 shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in beneficial ownership by an individual investor, which can be interpreted as a positive signal of confidence in the company. However, the capital raise through an at-the-money offering also implies dilution for existing shareholders, balancing the overall sentiment to moderately positive.

Positives

• A significant increase in beneficial ownership by an individual investor, Laurence W. Lytton, to 9.9% of Aprea Therapeutics, Inc. common stock.
• The direct purchase of 560,000 shares from the issuer in an at-the-money offering demonstrates a strong commitment and belief in the company's future by a substantial shareholder.

Negatives

• The at-the-money offering, while providing capital, results in dilution for existing shareholders due to the issuance of 560,000 new shares.

Risks

• Dilution of existing shareholders' equity due to the issuance of 560,000 new shares in the at-the-money offering.
• Potential for further capital raises through similar offerings, which could lead to additional dilution.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Laurence W. Lytton, a significant shareholder, purchased 560,000 shares directly from Aprea Therapeutics, Inc. in an at-the-money offering.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the issuance of new shares in the at-the-money offering. However, the increased stake by a significant individual investor could be seen as a vote of confidence.
• Company: Aprea Therapeutics, Inc. received capital from the at-the-money offering.

Key Dates

Keywords

Aprea Therapeutics, Laurence W. Lytton, Beneficial Ownership, Schedule 13G, Common Stock, Shareholder Stake, At-the-Money Offering, Equity Investment, Biotechnology